RxDoctor Payments DataLook up a doctor →

Gregory Brian, MD

Family Medicine · Alexandria, LANPI 1184616252

Payments from drug & device makers

$15,100in general payments, 2019–2025

Across 991 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • GSK$2K
  • Novo Nordisk$1K
  • Pfizer$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$790
  • plus $6K from 40 others

What the payments were for

  • Food & beverage$15,00499%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$15,100 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$229,371
Medicare patients
380
Services billed
10,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban191$126,412
OzempicSemaglutide85$106,798
JardianceEmpagliflozin91$84,611
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$47,719
FarxigaDapagliflozin Propanediol34$34,587
RybelsusSemaglutide24$31,511
MounjaroTirzepatide29$30,732
TrulicityDulaglutide29$29,158
XareltoRivaroxaban30$22,987
LinzessLinaclotide23$21,609
EntrestoSacubitril/Valsartan25$16,940
JanuviaSitagliptin Phosphate17$15,082
JanumetSitagliptin Phos/Metformin Hcl25$14,848
QuliptaAtogepant12$14,451
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen366$10,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,436$138,308109 claims
PfizerEliquis$1,098$126,412191 claims
Boehringer IngelheimJardiance, Combivent Respimat, Glyxambi$790$98,131125 claims
Lilly USA, LLCMounjaro, Trulicity$617$59,89058 claims
GSKTrelegy Ellipta, Breo Ellipta$1,701$55,39287 claims
AbbVieLinzess, Qulipta$2,786$36,06035 claims
AstraZenecaFarxiga$1,031$34,58734 claims
MerckJanuvia, Janumet$411$29,93142 claims
Johnson & JohnsonXarelto$139$22,98730 claims
NovartisEntresto$50$16,94025 claims
Sanofi-aventis U.S. LLCMultaq, Lantus$105$16,00257 claims
Astellas Pharma US IncMyrbetriq$377$9,76416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →